Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biologic therapy in inflammatory bowel disease.
Theede K, Dahlerup JF, Fallingborg J, Hvas CL, Kjeldsen J, Munck LK, Nordgaard-Lassen I; Danish Society of Gastroenterology and Hepatology. Theede K, et al. Among authors: munck lk. Dan Med J. 2013 Jun;60(6):B4652. Dan Med J. 2013. PMID: 23743116 Free article.
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Steenholdt C, et al. Among authors: munck lk. Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12. Dig Dis Sci. 2015. PMID: 25673037 Clinical Trial.
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Steenholdt C, et al. Among authors: munck lk. Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22. Gut. 2014. PMID: 23878167 Clinical Trial.
Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Steenholdt C, et al. Among authors: munck lk. J Crohns Colitis. 2015 Mar;9(3):238-45. doi: 10.1093/ecco-jcc/jjv004. Epub 2015 Jan 9. J Crohns Colitis. 2015. PMID: 25576753 Clinical Trial.
Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Steenholdt C, et al. Among authors: munck lk. J Crohns Colitis. 2015 Nov;9(11):1032-42. doi: 10.1093/ecco-jcc/jjv139. Epub 2015 Aug 5. J Crohns Colitis. 2015. PMID: 26245216 Clinical Trial.
Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis.
Wildt S, Munck LK, Vinter-Jensen L, Hanse BF, Nordgaard-Lassen I, Christensen S, Avnstroem S, Rasmussen SN, Rumessen JJ. Wildt S, et al. Among authors: munck lk. Inflamm Bowel Dis. 2006 May;12(5):395-401. doi: 10.1097/01.MIB.0000218763.99334.49. Inflamm Bowel Dis. 2006. PMID: 16670529 Clinical Trial.
121 results